Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Bullboard Posts
Comment by Benedict16thon Mar 02, 2019 5:31pm
91 Views
Post# 29433874

RE:Goodman Should Not Miss This Oopotunity Again

RE:Goodman Should Not Miss This Oopotunity AgainAll sounds well rock, but placing your business hopes on one deal for far too long is not a good financial practice though I too would hope for it to happen.
As well Mugmod, yes having lots of money at hand is very good but not doing much with all of the cash for a long time it is no good.  I am sure that among many  of the biotech  deal made by other companies for the past five Years where good ones.
I have been substantially invested with GUD for over five Years and I know very well in details what has GUD telegraphed to investors about their plans, but it has not happened period. Now they are changing the tune possibly too little too late. I am prepared to predict that unless GUD present an improved business model with more facts to investors, if it will come to a proxy fight they will lose as most other investors feel the same way. The straw poll on this forum is speaking loud and clear. So if GUD and the PR Company are humbling reading this forum pay attention as other large financial institutions are not happy either. Patient has its limits

Bullboard Posts